107 related articles for article (PubMed ID: 29324332)
21. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.
Sidelmann JJ; Kluft C; Krug AH; Winkler U; Jespersen J; Gram JB
Thromb Haemost; 2017 Apr; 117(4):700-705. PubMed ID: 28150855
[TBL] [Abstract][Full Text] [Related]
22. Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity.
Ajjan RA; Gamlen T; Standeven KF; Mughal S; Hess K; Smith KA; Dunn EJ; Anwar MM; Rabbani N; Thornalley PJ; Philippou H; Grant PJ
Blood; 2013 Jul; 122(1):134-42. PubMed ID: 23699598
[TBL] [Abstract][Full Text] [Related]
23. Impaired Fibrinolysis in Patients with Isolated Aortic Stenosis is Associated with Enhanced Oxidative Stress.
Siudut J; Natorska J; Wypasek E; Wiewiórka Ł; Ostrowska-Kaim E; Wiśniowska-Śmiałek S; Plens K; Legutko J; Undas A
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32630544
[TBL] [Abstract][Full Text] [Related]
24. Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BbetaGly15Cys (Hamamatsu II).
Kamijyo Y; Hirota-Kawadobora M; Yamauchi K; Terasawa F; Honda T; Ikeya M; Okumura N
Blood Coagul Fibrinolysis; 2009 Dec; 20(8):726-32. PubMed ID: 19809304
[TBL] [Abstract][Full Text] [Related]
25. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
Szczepaniak P; Zabczyk M; Undas A
PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
[TBL] [Abstract][Full Text] [Related]
26. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Konieczynska M; Fil K; Bazanek M; Undas A
Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
[TBL] [Abstract][Full Text] [Related]
27. Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma.
Undas A; Zubkiewicz-Usnarska L; Helbig G; Woszczyk D; Kozińska J; Dmoszyńska A; Podolak-Dawidziak M; Kuliczkowski K
Eur J Clin Invest; 2014 Jun; 44(6):557-66. PubMed ID: 24738991
[TBL] [Abstract][Full Text] [Related]
28. Prothrombotic plasma fibrin clot phenotype is associated with spontaneous echo contrast in atrial fibrillation: The role of protein carbonylation.
Słaboszewski M; Kolec R; Paszek E; Baran M; Undas A
Thromb Res; 2024 Jun; 240():109065. PubMed ID: 38908317
[TBL] [Abstract][Full Text] [Related]
29. Familial association of high levels of histidine-rich glycoprotein and plasminogen activator inhibitor-1 with venous thromboembolism.
Angles-Cano E; Gris JC; Loyau S; Schved JF
J Lab Clin Med; 1993 May; 121(5):646-53. PubMed ID: 8478593
[TBL] [Abstract][Full Text] [Related]
30. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
31. Reduced plasma fibrin clot permeability and susceptibility to fibrinolysis are associated with increased intima-media thickness in patients with primary antiphospholipid syndrome.
Asztabski M; Wypasek E; Ząbczyk M; Undas A
Thromb Res; 2014 Nov; 134(5):945-51. PubMed ID: 25194881
[TBL] [Abstract][Full Text] [Related]
32. A history of early stent thrombosis is associated with prolonged clot lysis time.
Pankiw-Bembenek O; Zalewski J; Goralczyk T; Undas A
Thromb Haemost; 2012 Mar; 107(3):513-20. PubMed ID: 22274545
[TBL] [Abstract][Full Text] [Related]
33. Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications.
Undas A; Zubkiewicz-Usnarska L; Helbig G; Woszczyk D; Kozińska J; Dmoszyńska A; Dębski J; Podolak-Dawidziak M; Kuliczkowski K
Blood Coagul Fibrinolysis; 2015 Sep; 26(6):621-7. PubMed ID: 26083985
[TBL] [Abstract][Full Text] [Related]
34. Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study.
Traby L; Kollars M; Eischer L; Eichinger S; Kyrle PA
PLoS One; 2012; 7(12):e51447. PubMed ID: 23240024
[TBL] [Abstract][Full Text] [Related]
35. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
36. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
[TBL] [Abstract][Full Text] [Related]
37. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
[TBL] [Abstract][Full Text] [Related]
38. Impaired fibrinolytic potential related to elevated alpha1-proteinase inhibitor levels in patients with pulmonary thromboembolism.
Gombás J; Kolev K; Tarján E; Machovich R
Ann Hematol; 2004 Dec; 83(12):759-63. PubMed ID: 15316758
[TBL] [Abstract][Full Text] [Related]
39. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
40. Reduced plasma fibrin clot permeability and susceptibility to lysis in patients with inflammatory bowel disease: a novel prothrombotic mechanism.
Owczarek D; Cibor D; Sałapa K; Głowacki MK; Mach T; Undas A
Inflamm Bowel Dis; 2013 Nov; 19(12):2616-24. PubMed ID: 24108112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
